Status:
COMPLETED
Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
We hypothesized that subjects with CYP2D6\*10 alleles may have a lower steady state levels of endoxifen due to reduced conversion of tamoxifen to endoxifen. Primary objectives: * To determine the st...
Eligibility Criteria
Inclusion
- Signed informed consent.
- At least 18 years of age.
- On tamoxifen for at least 3 months for adjuvant therapy.
- On a stable diet for past 1 week before blood sampling.
- Compliant with tamoxifen medication.
- Completed adjuvant chemotherapy and/or adjuvant radiation therapy.
Exclusion
- • Patients should not be on the list of medications for the last 1 week before accrual to the study
Key Trial Info
Start Date :
November 1 2005
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00717015
Start Date
November 1 2005
Last Update
April 3 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore